RX-044
RX-044 is a ROCK1/ROCK2 inhibitor with ROCK1 IC50 10.01 nM and ROCK2 IC50 9.68 nM, and demonstrates kinase selectivity. RX-044 induces reversible cell retraction, modulates cytoskeletal organization via F-actin depolymerization, inhibits cell contractility, and attenuates TGF-β2-induced cell migration. RX-044 preserves retinal ganglion cell survival, restores electroretinography responses, and ameliorates histopathological changes. RX-044 lowers intraocular pressure in a mouse ocular hypertension model. RX-044 shows no cytotoxicity in target cells. RX-044 exhibits initial ocular irritation that subsides with extended dosing. RX-044 can be used for the research of glaucoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C20H24N4
- 分子量:320.43
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
IC50 & Target
[1]|
ROCK1 10.01 nM (IC50) |
ROCK2 9.68 nM (IC50) |
体外実験
RX-044 (20 μM) shows no cytotoxicity in HTM cells, with cell viability maintained at 92.55%[1].
RX-044 (1 μM; 0-24 h) induces rapid, reversible retraction of HTM cells and regulates cytoskeletal structure via F-actin depolymerization[1].
RX-044 (1 μM; 24-48 h) inhibits HTM cell-mediated collagen gel contraction for at least 48 h, indicating a persistent inhibitory effect on cell contractility[1].
RX-044 (1 μM; 0-24 h) inhibits TGF-β2-induced migration of HTM cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HTM (human trabecular meshwork) cells
-
Concentration:1 μM (co-treated with 10 ng/mL TGF-β2)
-
Incubation Time:0, 10, 24 h
-
Result:Attenuated TGF-β2-induced HTM cell migration.
Reduced wound closure rates after 24 h of co-treatment.
体内実験
RX-044 (441 μM; topical eye drop administration once daily for 28 consecutive days) gradually restores elevated intraocular pressure in mice to normal levels starting from day 21 of administration; only mild conjunctival and iris hyperemia occurs at the initial stage of administration, and the irritant symptoms resolve completely after long-term continuous administration; meanwhile, it fully preserves the layered structure of the retina, increases the number of retinal ganglion cells labeled by BRN3A, restores the amplitudes of all characteristic waves in electroretinography, and ameliorates atrophic and inflammatory pathological damages of the cornea, iris and retina[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice with magnetic bead-induced ocular hypertension[1]
-
Dosage:441 μM
-
Administration:Topical ocular single administration; measured at 1, 2, 4, 6, 8, 24 h
-
Result:Exhibited prominent intraocular pressure-lowering activity, and reached the maximal IOP drop of 3.66 mmHg at 4 h with sustained weak hypotensive effect within 24 h.
-
Animal Model:Male C57BL/6 mice with polystyrene microsphere-induced ocular hypertension[1]
-
Dosage:441 μM
-
Administration:Topical ocular administration; once daily; for 28 days
-
Result:Restored elevated IOP to normal levels from day 21 and maintained stable long-term efficacy, and induced no abnormal body weight fluctuations in mice.
Triggered mild conjunctival hyperemia, iris congestion and anterior chamber flare on day 7, and eliminated all ocular irritation symptoms after sustained administration.
Protected complete layered retinal structure and avoided retinal edema, detachment and hemorrhage on OCT scans.
Elevated the count of BRN3A-positive retinal ganglion cells and thickened retinal INL/ONL layers to reverse retinal atrophy lesions.
Recovered amplitudes of all core ERG wavesl.
Alleviated corneal hyperplasia, iris vasodilation, inflammatory infiltration and retinal structural disorganization validated by eyeball H&E staining.
- Scratch/Wound-Healing Migration Assay
- Mammalian live/dead viability and cytotoxicity staining
- Cell migration
- Neural Crest/Neuronal Cell Migration Explant Assay
- Research Protocol for Cardiovascular Diseases
- Phalloidin F-actin cytoskeleton staining
- Cell Viability Determination by MTT Colorimetric Assay
- Cell Cytotoxicity Assay
- Zigmond Chamber Chemotaxis Assay
- Under-Agarose Cell Migration Assay
- Transwell/Boyden Chamber Migration Assay
- 3D Collagen/Hydrogel Matrix Migration Assay
- Cell-Exclusion Zone Migration Assay
- Dunn/Insall Chamber Chemotaxis Assay
化学情報
-
分子量 320.43
-
分子式 C20H24N4
-
SMILES
CN(CC1)CCC1C2=CC=C(NC3=CC=NC4=C3C(C)=CN4)C=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
RX-044 関連分類
HY-187204 関連分類
Powered by Bioz